Table 2.
Association analysis of rs3733591 with gout in NZ Māori, EP, WP and Caucasian sample sets and in the FHS cohorta
| Case genotypesb, n (OR) | Control genotypes, n (OR) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sample set | CC | CT | TT | C-allele frequency | CC | CT | TT | C-allele frequency | Genotypic P | Allelic P | P STRAT | Allelic OR, C allele (95% CI) |
| Māori | 101 (0.500) | 83 (0.411) | 18 (0.089) | 0.705 | 164 (0.500) | 138 (0.421) | 26 (0.079) | 0.710 | 0.92 | 0.86 | 0.93 | 0.98 (0.74 to 1.28) |
| EP | 119 (0.513) | 92 (0.397) | 21 (0.091) | 0.711 | 169 (0.506) | 139 (0.416) | 26 (0.078) | 0.714 | 0.82 | 0.92 | 0.80 | 0.99 (0.76 to 1.28) |
| WP | 39 (0.227) | 88 (0.512) | 45 (0.262) | 0.483 | 33 (0.239) | 57 (0.413) | 48 (0.348) | 0.446 | 0.17 | 0.36 | 0.65 | 1.16 (0.84 to 1.59) |
| NZ Caucasian | 217 (0.693) | 87 (0.278) | 9 (0.029) | 0.832 | 417 (0.656) | 196 (0.308) | 23 (0.036) | 0.810 | 0.49 | 0.23 | - | 1.17 (0.91 to 1.50) |
| FHS | 44 (0.657) | 21 (0.313) | 2 (0.030) | 0.813 | 3158 (0.670) | 1,385 (0.294) | 169 (0.036) | 0.817 | 0.92 | 0.91 | - | 0.98 (0.63 to 1.51) |
| ARIC | 117 (0.765) | 30 (0.196) | 6 (0.039) | 0.863 | 4902 (0.704) | 1,898 (0.272) | 168 (0.024) | 0.840 | 0.07 | 0.28 | - | 1.20 (0.86 to 1.67) |
aARIC = Atherosclerosis Risk in Communities study; CI = confidence interval; FHS = Framingham Heart Study; OR = odds ratio; EP = Eastern Polynesian; NZ = New Zealand; WP = Western Polynesian PSTRAT = STRAT test for association. bThere was successful genotyping of 202 Māori cases (88%) and 328 Māori controls (96%), 232 EP cases (89%) and 334 EP controls (96%), 172 WP cases (92%) and 138 WP controls (97%) and 313 NZ Caucasian cases (96%) and 636 NZ Caucasian controls (100%).